Glaceum

Focus: Glaceum is a Korean biotechnology company focused on metabolic diseases and age-related treatments with a pipeline spanning obesity, diabetes, osteoarthritis, and Parkinson's disease.

Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Glaceum

AI assessmentNot Hiring

No open roles listed right now. Follow Glaceum to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

HSG4112

Obesity

Phase 1

Clinical Trials (1)

NCT04732988A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112

Phase 1

Help build intelligence for Glaceum

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to emerging metabolic disease and obesity programs in Phase 1-2, with HSG4112 advancing to Phase 2 in obesity—a high-growth market
Opportunity to join an early-stage biotech with multi-indication potential (Vutiglabridin in both osteoarthritis and Parkinson's)
Based in Korea with growing biotech ecosystem, offering geographic diversification for pharma careers

Watch Out For

No active job openings currently listed, indicating minimal near-term hiring momentum
Pre-revenue stage with no disclosed funding, cash position, or financial stability data creates execution risk
Only 8 total clinical trials across pipeline with no Phase 3 programs—early stage means long development runway and uncertain near-term milestones

Generated by Claude from Glaceum's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

HSG4112

Obesity

Phase 1

Clinical Trials (1)

NCT05310032A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses

Phase 1

HSG4112

Obesity

Phase 1

Clinical Trials (1)

NCT04703764A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112

Phase 1

HSG4112

Obesity

Phase 1

Clinical Trials (1)

NCT04733001A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112

Phase 1

HGR4113

Diabetes Mellitus, Type 2

Phase 1

Clinical Trials (1)

NCT05642377A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HGR4113 in Healthy Subjects

Phase 1

HSG4112

Obesity

Phase 2

Clinical Trials (1)

NCT05197556A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients

Phase 2

Vutiglabridin

Parkinson Disease

Phase 2

Clinical Trials (1)

NCT06329141A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients